|
| |
Rapid
PSA Test is an immunochromatography based one step in
vitro test. It is designed for the rapid semi-quantitative
determination of human prostate specific antigen (PSA) in serum or
plasma specimens.
Alpha fetoprotein (AFP) is a
normal component of the fetal blood, produced by the embryo’s liver
cell. In adults, its concentration in the blood is very low. AFP is an
important index for clinical diagnosis of primary hepatocellular cancer
(PHC) since more than 70% PHC patients have elevated AFP blood
concentrations in early stage. AFP levels also increase in other
malignant tumors, such as testicular cancer. The test for serum AFP can
be a screening test in high incidence areas and clinically diagnostic
test for the liver cancer in the early stage. It can be used to
evaluate the treating effects of liver cancer and judge the prognosis. |
| Cat. No. |
Product
Name |
Specimen |
Fomat |
Packaging |
CE Marked |
|
72002
|
AFP
Test
|
Serum/Plasma
|
Strip
|
100 Tests/box
|
NO |
|
72002
|
AFP
Test
|
Whole Blood/Serum/Plasma
|
Strip
|
100 Tests/box
|
NO |
|
72002
|
AFP
Test
|
Serum/Plasma
|
Cassette
|
25 Tests/box
|
NO |
|
72002
|
AFP
Test
|
Whole Blood/Serum/Plasma
|
Cassette
|
25 Tests/box
|
NO |
|
72003 |
PSA Test |
Serum/Plasma
|
Strip |
100 Tests/box |
NO |
|
72004 |
PSA Test |
Whole Blood/ Serum/Plasma |
Strip |
100 Tests/box |
NO |
|
72003 |
PSA Test |
Serum/Plasma
|
Cassette |
25 Tests/box,
50 Tests/box |
NO |
|
72004 |
PSA Test |
Whole Blood/ Serum/Plasma |
Cassette |
25 Tests/box,
50 Tests/box |
NO |
 |
The
BioNexia® BTA cassette test is a
visual immunchromatographic rapid test for the qualitative detection of
bladder tumour antigens (BTA) in human urine specimens.
The determination of BTA in the urine is used to
assess the risk for cancer of the bladder. The test may be used as
screening test for the early detection of urocyst carcinoma as well as
for monitoring patients who have already been diagnosed with and
treated for bladder tumours. In these instances, the test supports
routine examinations of patients for the occurrence of relapses.
Incidence
Carcinomas of the urinary bladder represent
approx. 2-3% of all malign tumours in humans. After prostatic
carcinoma, bladder carcinoma is second in incidence of all tumour
diseases of the genitourinary system. The age-standardised attack rate
(incidence) reaches approx. 19 per 100,000 inhabitants and year
(Europe), although distinct country-specifi c differences are observed
in some parts. In younger patients, this rate is considerably lower
than in elderly ones, reaching its peak in the 7th and 8th decade of
life. Incidence in men is approx. three times as high as in
women.
Etiology
Among the factors increasing the risk of
urinary bladder carcinoma are smoking, chronic cystitis, exposure to
aromatic amines at work (e.g. hairdressers, chemical, leather and paint
industry, pest control, and others)3, radiotherapy of the lesser
pelvis, bilharziosis, Balkan nephropathy, chronic interstitial
nephritis as well as long-term application of certain medications
(chlornaphazine, phenacetine, cyclophosphamide), some of which have
been removed from the market.
Clinical Symptoms
Micro or macro hematuris occurs in approx.
80% of patients, although detection of both forms often occurs only
intermittently. Other frequent symptoms indicating a carcinoma of the
urinary bladder are dysuric micturition difficulties, particularly in
cases where no improvement is achieved with antibiosis. In advanced
stages, pain and urinary retention and the accompanying problems may
occur.
|
| ART. CODE |
NAME |
SIZE |
CE MARKED |
| BM-BTA-2D |
BioNexia
BTA Test |
10
Tests |
YES |
Do you have any other question? Contact us and we will help you.
|
The .pdf version of this page
is available in our
our products
page.
|
| |
|
